ARS Pharmaceuticals, Inc. Balance Sheet
SPRY / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
ARS Pharmaceuticals, Inc. had $328M in total assets and $114M in shareholders' equity as of FY2025. Total debt was $96M against $41M in cash, resulting in $55M net debt.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $41.3M | $50.8M | $71.0M | $210.5M | $60.1M | $386.6M |
| Accounts Receivable | $25.3M | $8.2M | - | - | - | - |
| Inventory | $31.4M | $10.5M | - | - | - | - |
| Current Assets | $284.9M | $334.3M | $231.7M | $277.7M | $60.7M | $390.7M |
| PP&E (Net) | $2.5M | $1.1M | $574.0K | $329.0K | $72.0K | $1.6M |
| Total Assets | $327.7M | $351.2M | $233.2M | $281.4M | $61.4M | $394.8M |
| Current Liabilities | $39.1M | $23.4M | $2.4M | $5.4M | $8.2M | $9.6M |
| Total Debt | $96.4M | $0 | - | - | - | - |
| Shareholders' Equity | $114.3M | $256.8M | $230.8M | -$31.3M | -$31.3M | -$14.1M |